Last reviewed · How we verify
nebulised liposomal amphotericin B
At a glance
| Generic name | nebulised liposomal amphotericin B |
|---|---|
| Sponsor | Erasmus Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole (PHASE3)
- Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study) (PHASE1)
- Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded). (PHASE2)
- Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia (PHASE2)
- Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nebulised liposomal amphotericin B CI brief — competitive landscape report
- nebulised liposomal amphotericin B updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI